Aurinia Pharmaceuticals Inc. (AUPH)
A
Pipeline Grade
Financial Position (from SEC Filings)
$41.0M
Cash & Equivalents
$32.6M
Quarterly Burn Rate
$1,998M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
VOCLOSPORIN
LUPKYNIS |
APPROVED | Adolescent Lupus Nephritis, Covid19, Drug-drug Interaction, Dry Eye, Dry Eye Syndrome, Focal Segmental Glomerulosclerosis, Keratoconjunctivitis Sicca, Kidney Diseases, Kidney Transplant Infection, Lupus Nephritis, Myasthenia Gravis, Generalized, Pediatric Lupus Nephritis, Psoriasis, Renal Transplantation, Volunteers |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07596901 | Study of Aritinercept in Patients With Generalized Myasthenia Gravis | PHASE2 | Recruiting | 81 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.